November 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Mokhtar Tazik: Connecting Clinical Demand with Plasma Collection and Fractionation Capacity

AI generated

Nov 12, 2026, 14:35

Mokhtar Tazik: Connecting Clinical Demand with Plasma Collection and Fractionation Capacity

Mokhtar Tazik, Plasma Bussiness Manager and Local Biotest QA at DAC, shared a post on LinkedIn:

“From Real-World Evidence to Better Patient Access: Rethinking Plasma Collection Strategies.

Real-World Data (RWD) and Real-World Evidence (RWE) are playing an increasingly important role in regulatory decision-making and healthcare policy.

Initiatives such as EMA’s DARWIN EU network and the FDA’s expanding use of RWE reflect an important shift: moving beyond historical drug consumption figures towards evidence-based healthcare planning.

This evolution has particular strategic significance for the plasma industry and PDMPs.

RWE can help address three fundamental questions:

1. How much plasma do we really need?

Understanding current clinical needs and anticipating future patient demand can help countries/world determine plasma collection targets based on actual and clinical requirements, rather than relying just on historical consumption.

2. To what extent do patients have access to PDMPs?

Analysis of real world data can reveal treatment gaps, interruptions, dose reductions, drug efficacy and the impact of product shortages on patient care.

3. How can we strengthen supply chain resilience?

Linking patient treatment data with plasma collection strategies and fractionation capacity can help better align current gaps between plasma supply with actual clinical demand.

The strategic message is clear:

RWE/RWD based approaches can help us better understand how current plasma collection compares with collection targets and, ultimately, how well it meets patients’ actual clinical need.

For Low and Middle Income Countries (LMICs), developing the infrastructure for generating and analysing RWE beside plasma collection infrastructure can create a stronger link between four essential elements:

Clinical Needs – Plasma Collection Volumes – PDMP Availability – Sustainable Patient Access

Ultimately, RWE can serve as a valuable tool for policymakers to identify and quantify the GAP between available plasma resources and the plasma needed to calculate real clinical need and ensure sustainable patient access to PDMPs.

Better data. Smarter planning. Increased plasma collection. More sustainable patient access to PDMPs.”

Proceed to the video attached to the post.

Stay updated with Hemostasis Today.